
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is forecasted to see a steady increase in GAAP earnings, projecting $4.73 per diluted share for 2025 and $5.17 for 2026, indicating strong anticipated growth driven by the Human Nutrition and Health segment. The company's 2Q25 results showcased top-line revenue of $255.5 million, surpassing estimates and showing year-over-year growth, along with continuous improvements in gross and net margins expected in the near future. Additionally, Balchem is projected to achieve a debt-free status by the end of the coming year, which may enable the company to consider strategic mergers and acquisitions, thereby enhancing its financial stability and growth potential.
Bears say
Balchem Corp's financial outlook appears negative due to a decline in its P/E multiple from 39.6x to 37.9x, which reflects a deteriorating market sentiment compared to the prior period. The company faces several risks, including slower-than-anticipated growth in its baseline businesses, inflationary pressures, and challenges surrounding the launch of new nutrition products, which collectively could hamper future performance. Additionally, recent sales in key segments, such as the animal health and nutrition segment, missed estimates with reported sales of $56.4M against an expected $60M, indicating potential operational weaknesses.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares